Oman Diabetes Care Devices Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

Oman's diabetes care devices market operates within the broader Middle East and Africa regional framework, where the MEA market is estimated at approximately USD 2.53 billion in 2025, with the GCC and UAE sub-region valued at roughly USD 3.12 billion in 2024. The Oman-specific market, positioned at approximately USD 65 million in prior-year estimates, is projected to reach roughly USD 40.5 million by 2026, reflecting its status as a mid-tier national market within the Gulf Cooperation Council. The market spans blood glucose monitoring systems, insulin delivery devices, continuous glucose monitoring systems, and associated consumables such as test strips and lancets.

• •Country-level market embedded within a MEA regional diabetes care devices industry estimated at USD 2.53 billion in 2025
• •Market covers blood glucose monitors, insulin delivery devices, continuous glucose monitors, and related consumables
• •Growth trajectory of 9.91% CAGR positioned above global market averages driven by regional diabetes burden

The primary growth engine is the high and rising prevalence of diabetes across the Omani population, consistent with elevated regional rates observed throughout the Middle East and North Africa. Government-led healthcare modernization programs and expanded insurance coverage are improving patient access to advanced diabetes management devices. Additionally, growing clinical and patient awareness of the advantages of continuous glucose monitoring and insulin pump therapy over conventional fingerstick monitoring is accelerating adoption of premium device categories.

• •High national diabetes prevalence rates consistent with MEA regional trends supporting sustained device demand
• •Government healthcare infrastructure investment and expanded insurance reimbursement broadening patient access
• •Rising clinical preference for continuous glucose monitoring and connected insulin delivery technology driving category migration

The market is broadly segmented into blood glucose monitoring systems, continuous glucose monitoring devices, insulin delivery systems including pens and pumps, and self-monitoring consumables. Within Oman, demand is concentrated in major urban centers including Muscat and Sohar, where healthcare infrastructure density is highest and specialty endocrinology services are most accessible. Compared to larger GCC markets such as Saudi Arabia and the UAE, Oman presents a smaller but rapidly growing opportunity, with per-capita device adoption rates tracking behind regional leaders while exhibiting stronger relative growth momentum.

• •Key device categories: blood glucose monitoring systems, continuous glucose monitors, insulin pumps and pens, and associated test strips
• •Urban demand concentrated in Muscat and regional hospital centers with greatest endocrinology service availability
• •Per-capita device adoption trailing larger GCC markets but exhibiting higher relative growth rates

Who are the notable companies in the industry?

The competitive structure of the Oman diabetes care devices market exhibits moderate fragmentation, with supply chains shaped by both large multinational healthcare technology firms operating through regional distribution agreements and smaller specialty producers focusing on consumables and monitoring components. The market draws on established electrochemical sensor and microfluidic cartridge manufacturing processes as the dominant technology routes, with integrated producers typically controlling upstream sensor and reagent chemistry. Regional capacity is heavily concentrated in North America, Europe, and parts of East Asia for advanced device manufacturing, while local assembly, customization, and distribution networks in Oman and the wider GCC serve as the primary market access layer for end-users.

• •Moderately fragmented supply base with multinational technology providers and regional distributors shaping commercial access
• •Electrochemical biosensor and microfluidic assay technologies represent the dominant manufacturing process routes for core monitoring devices
• •Advanced device manufacturing capacity concentrated in North America, Europe, and East Asia; GCC-based distribution and service networks provide localized market access

What are the recent trends and outlook?

The market outlook remains strongly positive, with the global diabetes care devices industry projected to reach approximately USD 61.22 billion by 2030, and regional MEA markets expected to sustain elevated growth rates over the coming decade. Key trends include accelerating integration of digital connectivity and smartphone-linked glucose monitoring platforms, expanding government chronic disease management programs, and growing demand for minimally invasive and automated insulin delivery solutions. Regulatory harmonization and evolving reimbursement frameworks across the GCC will play an increasingly important role in shaping market entry and pricing dynamics.

• •Global diabetes care devices market projected to reach USD 61.22 billion by 2030, supporting regional supply and technology transfer trends
• •Digital glucose monitoring platforms and connected device ecosystems emerging as the primary product innovation frontier
• •GCC regulatory alignment and expanding government chronic disease management spending expected to accelerate market formalization